BRPI0516727A - métodos para tratar um linfoma positivo em cd30 , para inibir o crescimento de uma célula que expressa cd30, e para tratar ou prevenir uma doença - Google Patents

métodos para tratar um linfoma positivo em cd30 , para inibir o crescimento de uma célula que expressa cd30, e para tratar ou prevenir uma doença

Info

Publication number
BRPI0516727A
BRPI0516727A BRPI0516727-2A BRPI0516727A BRPI0516727A BR PI0516727 A BRPI0516727 A BR PI0516727A BR PI0516727 A BRPI0516727 A BR PI0516727A BR PI0516727 A BRPI0516727 A BR PI0516727A
Authority
BR
Brazil
Prior art keywords
treating
methods
inhibiting
disease
growth
Prior art date
Application number
BRPI0516727-2A
Other languages
English (en)
Inventor
Tibor Keler
Elke Pogge Von Strandmann
Andreas Engert
Peter Borchmann
Boris Boeell
Original Assignee
Medarex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medarex Inc filed Critical Medarex Inc
Publication of BRPI0516727A publication Critical patent/BRPI0516727A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Abstract

MéTODOS PARA TRATAR UM LINFOMA POSITIVO EM CD3O, PARA INIBIR O CRESCIMENTO DE UMA CéLULA QUE EXPRESSA CD3O, E PARA TRATAR OU PREVENIR UMA DOENçA. Métodos para tratar linfomas caracterizados pela expressão de CD3O usando anticorpos anti-CD3O e inibidores de proteassoma em combinação são divulgados.
BRPI0516727-2A 2004-10-01 2005-09-30 métodos para tratar um linfoma positivo em cd30 , para inibir o crescimento de uma célula que expressa cd30, e para tratar ou prevenir uma doença BRPI0516727A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61528404P 2004-10-01 2004-10-01
PCT/US2005/035477 WO2006039644A2 (en) 2004-10-01 2005-09-30 Methods of treating cd30 positive lymphomas

Publications (1)

Publication Number Publication Date
BRPI0516727A true BRPI0516727A (pt) 2008-09-16

Family

ID=35929979

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0516727-2A BRPI0516727A (pt) 2004-10-01 2005-09-30 métodos para tratar um linfoma positivo em cd30 , para inibir o crescimento de uma célula que expressa cd30, e para tratar ou prevenir uma doença

Country Status (13)

Country Link
US (1) US7790160B2 (pt)
EP (1) EP1802345A2 (pt)
JP (1) JP2008514730A (pt)
KR (1) KR20070083899A (pt)
CN (1) CN101056655A (pt)
AU (1) AU2005292227A1 (pt)
BR (1) BRPI0516727A (pt)
CA (1) CA2582016A1 (pt)
IL (1) IL182260A0 (pt)
MX (1) MX2007003533A (pt)
NO (1) NO20071714L (pt)
WO (1) WO2006039644A2 (pt)
ZA (1) ZA200703154B (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003059282A2 (en) 2002-01-09 2003-07-24 Medarex, Inc. Human monoclonal antibodies against cd30
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
EP1802345A2 (en) 2004-10-01 2007-07-04 Medarex, Inc. Methods of treating cd30 positive lymphomas
MX2007009940A (es) 2005-02-18 2007-10-10 Medarex Inc Anticuerpos monoclonales que carecen de residuos fucosilo contra cd30.
WO2006116246A2 (en) * 2005-04-25 2006-11-02 Medarex, Inc. Method of treating cd30 positive lymphomas
EP1976883B1 (en) * 2006-01-17 2012-10-03 Medarex, Inc. Monoclonal antibodies against cd30 lacking in fucosyl and xylosyl residues
WO2007143600A2 (en) * 2006-06-05 2007-12-13 Incyte Corporation Sheddase inhibitors combined with cd30-binding immunotherapeutics for the treatment of cd30 positive diseases
EP2155231B1 (en) * 2007-04-10 2012-08-08 The Johns Hopkins University Imaging and therapy of virus-associated tumors
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
MX342405B (es) 2010-06-03 2016-09-28 Pharmacyclics Inc El uso de inhibidores de la tirosina quinasa de bruton (btk).
CA2864092C (en) 2012-02-10 2021-06-29 Seattle Genetics, Inc. Detection and treatment of cd30+ cancers
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
AU2013293087B2 (en) 2012-07-24 2017-08-31 Pharmacyclics Llc Mutations associated with resistance to inhibitors of Bruton's tyrosine kinase (BTK)
ES2728578T3 (es) 2013-09-20 2019-10-25 Bristol Myers Squibb Co Combinación de anticuerpos anti-LAG-3 y anticuerpos anti-PD-1 para tratar tumores
TWI660739B (zh) * 2013-10-25 2019-06-01 製藥公司 使用布魯頓氏酪胺酸激酶抑制劑之治療及免疫療法
WO2015085289A1 (en) * 2013-12-06 2015-06-11 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-cd30 antibodies
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
PT3116909T (pt) * 2014-03-14 2020-01-30 Novartis Ag Moléculas de anticorpos para lag-3 e suas utilizações
AU2015287559A1 (en) * 2014-07-11 2017-01-12 Expression Pathology, Inc. SRM/MRM assay for the tumor necrosis factor receptor superfamily member 8 (CD30) protein
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
CA3032011A1 (en) * 2016-08-04 2018-02-08 Millennium Pharmaceuticals, Inc. Combination of proteasome inhibitors and anti-cd30 antibodies
CN106854245A (zh) * 2016-12-28 2017-06-16 无锡傲锐东源生物科技有限公司 抗cd30蛋白单克隆抗体及其用途
CA3060984A1 (en) 2017-05-30 2018-12-06 Bristol-Myers Squibb Company Treatment of lag-3 positive tumors
EP3630179A2 (en) 2017-05-30 2020-04-08 Bristol-Myers Squibb Company Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody
WO2019148410A1 (en) * 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1 antibodies
WO2022187078A1 (en) 2021-03-01 2022-09-09 Nantbio, Inc. Anti-cd30 monoclonal antibodies and chimeric antigen receptors

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991007437A2 (en) 1989-11-20 1991-05-30 Parker, David, L. Improved cd-30 antibodies and fragments thereof
US5165923A (en) 1989-11-20 1992-11-24 Imperial Cancer Research Technology Methods and compositions for the treatment of hodgkin's disease
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
WO1994025585A1 (en) 1993-04-26 1994-11-10 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0546073B1 (en) 1990-08-29 1997-09-10 GenPharm International, Inc. production and use of transgenic non-human animals capable of producing heterologous antibodies
DE4200043A1 (de) 1991-11-11 1993-05-13 Stein Harald Prof Dr Lymphoides cd30-antigen (ki-1), dessen protein- und die zugehoerige nucleotidsequenz, seine herstellung sowie mittel zur diagnose und untersuchung von tumoren
ATE311895T1 (de) 1992-05-26 2005-12-15 Immunex Corp Neue zytokine die cd30 binden
WO1994004189A1 (en) 1992-08-25 1994-03-03 Medac Gesellschaft Fur Klinische Spezialpräparate Mbh Antibody/radioisotope conjugate for tumor diagnosis and/or therapy
DE4337197C1 (de) 1993-10-30 1994-08-25 Biotest Pharma Gmbh Verfahren zur selektiven Herstellung von Hybridomazellinien, die monoklonale Antikörper mit hoher Zytotoxizität gegen humanes CD16-Antigen produzieren, sowie Herstellung bispezifischer monoklonaler Antikörper unter Verwendung derartiger monoklonaler Antikörper und des CD30-HRS-3-Antikörpers zur Therapie menschlicher Tumore
WO1996022384A1 (en) 1995-01-18 1996-07-25 Boehringer Mannheim Gmbh Anti-cd 30 antibodies preventing proteolytic cleavage and release of membrane-bound cd 30 antigen
DE19543039C1 (de) 1995-11-08 1996-11-21 Medac Klinische Spezialpraep Rekombinante Liganden für das menschliche Zellmembran-Antigen CD30
KR100643058B1 (ko) 1996-12-03 2006-11-13 아브게닉스, 인크. 복수의 Ｖн 및 Ｖк 영역을 함유하는 인간 면역글로불린 유전자좌를 갖는 트랜스제닉 포유동물 및 이로부터 생성된 항체
WO1999040187A1 (de) 1998-02-06 1999-08-12 Hinrich Abken Nukleinsäuren zur modulation zellulärer aktivierung
DE19937264A1 (de) 1999-08-06 2001-02-15 Deutsches Krebsforsch F¶v¶-Antikörper-Konstrukte
US6652854B2 (en) 2000-08-08 2003-11-25 Immunex Corporation Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L
WO2002017979A2 (en) 2000-08-29 2002-03-07 Noveon Ip Holdings Corp. Dehydrated hydrogels
US7090843B1 (en) 2000-11-28 2006-08-15 Seattle Genetics, Inc. Recombinant anti-CD30 antibodies and uses thereof
KR100988949B1 (ko) * 2001-10-25 2010-10-20 제넨테크, 인크. 당단백질 조성물
WO2003059282A2 (en) 2002-01-09 2003-07-24 Medarex, Inc. Human monoclonal antibodies against cd30
EP1532175B1 (en) 2002-03-22 2012-10-17 Aprogen, Inc. Humanized antibody and process for preparing the same
FR2844513B1 (fr) 2002-09-13 2007-08-03 Lab Francais Du Fractionnement Anticorps pour adcc et induisant la production de cytokines.
EP1802345A2 (en) 2004-10-01 2007-07-04 Medarex, Inc. Methods of treating cd30 positive lymphomas
MX2007009940A (es) 2005-02-18 2007-10-10 Medarex Inc Anticuerpos monoclonales que carecen de residuos fucosilo contra cd30.

Also Published As

Publication number Publication date
CN101056655A (zh) 2007-10-17
NO20071714L (no) 2007-06-28
CA2582016A1 (en) 2006-04-13
WO2006039644A3 (en) 2006-08-10
MX2007003533A (es) 2007-05-23
JP2008514730A (ja) 2008-05-08
WO2006039644A2 (en) 2006-04-13
EP1802345A2 (en) 2007-07-04
US20060177442A1 (en) 2006-08-10
AU2005292227A1 (en) 2006-04-13
US7790160B2 (en) 2010-09-07
IL182260A0 (en) 2007-07-24
ZA200703154B (en) 2008-09-25
KR20070083899A (ko) 2007-08-24

Similar Documents

Publication Publication Date Title
BRPI0516727A (pt) métodos para tratar um linfoma positivo em cd30 , para inibir o crescimento de uma célula que expressa cd30, e para tratar ou prevenir uma doença
NL301145I2 (nl) Tirbanibulin
CY1122522T1 (el) Μετα αρσενικωδες νατριο για χρηση στην αγωγη του πολλαπλου μυελωματος
MX2009004986A (es) Metodos de tratamiento de anemia hemolitica.
MX2019005150A (es) Inhibidores de la tirosina-cinasa de bruton.
WO2010031056A3 (en) Methods and compositions for modulating ire1, src, and abl activity
GT200600407A (es) Compuestos ppar activos
TW200600087A (en) Methods and compositions for treating amyloid-related diseases
TW200716624A (en) Compounds for modulating TRPV3 function
CL2007003649A1 (es) Un conjugado de molecula asociado a anticuerpo monoclonal humano anti-cd70; composicion que comprende al conjugado de molecula asociado a anticuerpo; metodo de inhibicion del crecimiento de celulas tumorales que expresan cd70.
NO20075865L (no) Innelukket behandlingskjemikalie og fremgangsmate for forsinket frigivelse av samme
UA96115C2 (uk) Спосіб і композиція для лікування амілоїдогенних захворювань
SG165387A1 (en) 5-lipoxygenase-activating protein (flap) inhibitors
TW200714283A (en) Method and composition for treating peripheral vascular diseases
EA200200105A1 (ru) СОЕДИНЕНИЯ, МОДУЛИРУЮЩИЕ АКТИВНОСТЬ PPARγ;
BR0312785A (pt) Tratamento de desordens relacionadas a tnf(alfa)
SG170826A1 (en) Oral dosage forms including an antiplatelet agent and an acid inhibitor
BRPI0517091B8 (pt) composto 4-hidroxibenzomorfano substituído na posição-3 por carboxamida ou tiocarboxamida
EA200801942A1 (ru) Способ предотвращения или уменьшения риска возникновения рака с использованием пептидов на основе белков нервных волокон
DE502004002571D1 (de) Substituierte 3-pyrrolidin-indol-derivate
BRPI0607351A2 (pt) métodos para tratamento de linfomas empregando uma combinação de agente quimioterapêutico e il-2 e opcionalmente um anticorpo anti-cd20
TW200716015A (en) Methods and apparatuses for sealing ophthalmic lens packages
NO20070351L (no) Materialer og fremgangsmater for forbedring av skalldyrhelse, -immunitet og -vekst
WO2009023846A3 (en) Methods for heat shock protein dependent cancer treatment
UA103456C2 (ru) Способ повышения толерантности растений

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.